Brief: Quantum Genomics FY Net Loss Narrows To 9.1 Million Euros

Quantum Genomics SA

26/03/2020 17:45

March 26 (Reuters) - Quantum Genomics SA  ALQGC.PA :
    * FY 2019 SHOW -EUR10.8 MILLION IN OPERATING LOSS COMPARED
TO
-EUR13.6 MILLION YEAR AGO
    * QUANTUM GENOMICS SECURED NEW FINANCING, PUBLISHED ITS
FINANCIAL
STATEMENTS FOR FISCAL YEAR 2019 AND PROVIDES 2019 HIGHLIGHTS
    * DESPITE CURRENT PUBLIC HEALTH CRISIS AND ANY FINANCIAL
CONSEQUENCES IT MAY HAVE, FACT THAT QUANTUM GENOMICS HAS SECURED
NEW FINANCING CONFIRMS THAT INVESTORS REMAIN CONFIDENT IN ITS
OUTLOOK
    * THIS ROUND OF FINANCING, WHICH INCLUDES A LOAN NOT TO
EXCEED EUR
8 MILLION AND ISSUE OF SHARE SUBSCRIPTION WARRANTS, WAS SECURED
AS PART OF AN AGREEMENT WITH NEGMA GROUP LTD, DATED MARCH 26,
2020
    * THIS FINANCING WILL BE RENEWABLE TWO TIMES, BY MUTUAL
CONSENT
BETWEEN QUANTUM GENOMICS AND NEGMA GROUP LTD, AND WILL PROVIDE
QUANTUM GENOMICS WITH A MAXIMUM OF EUR24 MILLION
    * FY FREE CASH FLOW (NET CASH FROM OPERATING ACTIVITIES) WAS
-EUR10.7 MILLION DURING THIS PERIOD
    * FY NET LOSS OF EUR 9.1 MILLION VERSUS LOSS OF EUR 11.9
MILLION
YEAR AGO
    * COMPANY HAS NO FINANCIAL LIABILITIES AND AVAILABLE CASH
FLOW
REACHED EUR 11.2 MILLION AT END-DEC 2019 VERSUS EUR14.8 MILLION
AT DEC 31, 2018
    * 2019 FREE CASH FLOW (NET CASH FROM OPERATING ACTIVITIES)
WAS
-EUR10.7 MILLION

Source text: https://bit.ly/3alKLKX
Further company coverage:  ALQGC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))